FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * ADAMS JULIAN 2. Issuer Name and Ticker or Trading Symbol Gamida Cell Ltd. [ GMDA ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)
C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)
7/27/2022
(Street)
BOSTON, MA 02116
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares  7/27/2022 (1)   A    48500 (2) A $0.00  124650  D   
Ordinary Shares  7/27/2022 (1)   A    68800 (3) A $0.00  193450  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Share Option (Right to Buy)  $2.93  7/27/2022 (4)   A     291100       (5) 7/26/2032  Ordinary Shares  291100  $0.00  291100  D   

Explanation of Responses:
(1)  The restricted stock unit ("RSU") award was approved by the Board of Directors of the Issuer on January 28, 2022, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on July 27, 2022.
(2)  These shares represent an RSU award, which shall vest in three equal annual installments commencing on July 27, 2023. The vesting of the RSUs is subject to the Reporting Person's continuous service through such vesting date.
(3)  These shares represent an RSU award, which shall vest in two equal annual installments commencing on December 31, 2022. The vesting of the RSUs is subject to the Reporting Person's continuous service through such vesting date.
(4)  The option grant was approved by the Board of Directors of the Issuer on January 28, 2022, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on July 27, 2022.
(5)  One fourth (1/4th) of the shares subject to the option award shall vest on July 27, 2023, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
ADAMS JULIAN
C/O GAMIDA CELL LTD.
116 HUNTINGTON AVENUE
BOSTON, MA 02116
X
Chief Executive Officer

Signatures
/s/ Joshua F. Patterson, Attorney-in-Fact 8/10/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Gamida Cell Charts.
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Gamida Cell Charts.